Loading organizations...
Key people at Accel-Rx Health Sciences Accelerator.
Accel-Rx Health Sciences Accelerator is a national organization fostering early-stage health sciences companies in Canada. It identifies high-potential technologies from research centers, providing a platform for commercialization. Accel-Rx offers seed funding and support services, including expert evaluation and mentorship, preparing ventures for Series A investment. This approach accelerates groundbreaking health innovations by leveraging existing research infrastructure and strategic guidance.
Established in 2014, Accel-Rx was formed by health-related Centres of Excellence for Commercialization and Research (CECRs). The founding premise addressed Canada's research base often lacked sufficient capital, strategic partners, and experienced guidance for promising firms. This collaborative effort aimed to create a national mechanism to anchor these companies within the Canadian life sciences sector, addressing critical gaps in the commercialization pathway.
Accel-Rx serves emerging health science companies with potential for substantial healthcare impact. Its mission maximizes new enterprise creation and cultivates strong, domestic anchor companies. Beyond capital, the organization actively fosters investor relationships and delivers programs like networking and mentorship, ensuring portfolio companies are well-resourced and positioned for enduring success within the ecosystem.
Key people at Accel-Rx Health Sciences Accelerator.
Accel-Rx Health Sciences Accelerator has 2 tracked investments across 2 companies. The latest tracked deal is $7.0M Series A in Inversago Pharma in July 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2018 | Inversago Pharma | $7.0M Series A | AmorChem, Jamie Stiff | Forbion, ED Mathers, Anges Québec, JDRF T1D Fund, Tarnagulla Ventures |
| Feb 18, 2016 | ScarX Therapeutics | $2.0M Series A | — | BDC Capital, Parimal Nathwani |